Genomics and proteomics in renal cell carcinoma: diagnosis, prognosis, and treatment selection.
The term renal cell carcinoma (RCC) once referred to a single entity but now encompasses a spectrum of diverse epithelial tumors with a common derivation from the renal tubular epithelium. The variable course of RCC remains problematic for patient management, despite advances in diagnosis and improved understanding of prognostic factors. However, powerful, high-throughput technologies that now analyze the entire genome and proteome promise to elucidate the heterogeneity of this disease and eventually enable a patient-tailored, individualized medicine. This review considers the clinical relevance and general significance of gene expression and protein-profiling studies.
Jones
Jon
J
Department of Urology, David Geffen School of Medicine at UCLA, 66-118 Center for Health Sciences, Box 951738, Los Angeles, CA 90095, USA.
Pantuck
Allan J
AJ
D002292:Carcinoma, Renal Cell / Q000175:diagnosis* / Q000628:therapy*; D023281:Genomics; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000628:therapy*; D011379:Prognosis; D040901:Proteomics